Form 4: AbbVie Executive Timothy J. Richmond Reports Stock Sales and Option Exercise
SEC Form 4 Filing
EVP and Chief HR Officer of AbbVie, Timothy J. Richmond, reports the sale of common stock and exercise of stock options on February 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 26, 2025, Timothy J. Richmond, EVP and Chief HR Officer of AbbVie Inc., reported the sale of several blocks of AbbVie common stock.
- These sales were executed under a Rule 10b5-1 trading plan established on November 27, 2024.
- Richmond sold 1,400 shares at an average price of $202.06, 4,781 shares at an average price of $202.93, 1,526 shares at an average price of $203.64, 4,308 shares at an average price of $201.97, 13,073 shares at an average price of $202.92 and 4,829 shares at an average price of $203.63.
- In addition to the sales, Richmond exercised options to acquire 22,210 shares of common stock at a price of $114.36 per share.
- Following these transactions, Richmond directly owns 44,284 shares of AbbVie common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 plan and do not necessarily reflect a change in the executive's outlook on the company.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into an executive's perspective on the company's performance and future prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
- Sales under 10b5-1 plans are a common practice among executives at companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK) to diversify their holdings and manage personal finances.
- The size and frequency of these transactions are generally in line with industry norms for executives at similarly sized companies.
Stakeholder Impact
- The stock sales could have a minor, temporary impact on the stock price.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/15/2019 | Date option exercisable |
| 11/27/2024 | Date of Rule 10b5-1 plan establishment |
| 02/26/2025 | Date of stock sales and option exercise |
| 02/14/2028 | Date option expires |
| 02/28/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.